Gabriele M. Cerrone
CIK: 0001139306
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (19 total)
- Jul 21, 2026TLSA
Tiziana Life Sciences Ltd
Purchase(P)Indirect42.4K shares at avg. $0.99$42K - Jul 21, 2026OKYO
OKYO Pharma Ltd
Purchase(P)Indirect22.5K shares at avg. $1.45$33K - Jul 21, 2026TLSA
Tiziana Life Sciences Ltd
Award(A)Indirect42.4K shares at avg. $0.99$42K - Jul 21, 2026OKYO
OKYO Pharma Ltd
Award(A)Indirect22.5K shares at avg. $1.45$33K - Jul 20, 2026OKYO
OKYO Pharma Ltd
Purchase(P)Indirect25K shares at avg. $1.40$35K - Jul 20, 2026OKYO
OKYO Pharma Ltd
Award(A)Indirect25K shares at avg. $1.40$35K - Jun 12, 2026TLSA
Tiziana Life Sciences Ltd
Purchase(P)Indirect15K shares at avg. $1.11$17K - Jun 12, 2026TLSA
Tiziana Life Sciences Ltd
Award(A)Indirect15K shares at avg. $1.11$17K - Jun 8, 2026OKYO
OKYO Pharma Ltd
Award(A)Indirect300K shares at avg. $1.72$516K - Jun 13, 2025ACUT
Accustem Sciences Inc.
Purchase(P)Indirect2K shares at avg. $1.00$2K - Jun 13, 2025ACUT
Accustem Sciences Inc.
Purchase(P)Indirect400 shares at avg. $1.10$440 - Jun 12, 2025ACUT
Accustem Sciences Inc.
Purchase(P)Indirect9K shares at avg. $0.83$7K - Jun 11, 2025ACUT
Accustem Sciences Inc.
Purchase(P)Indirect28.2K shares at avg. $0.39$11K - Apr 9, 2025ACUT
Accustem Sciences Inc.
Purchase(P)Indirect3K shares at avg. $0.67$2K - Apr 8, 2025ACUT
Accustem Sciences Inc.
Purchase(P)Indirect35K shares at avg. $0.67$23K - Apr 7, 2025ACUT
Accustem Sciences Inc.
Purchase(P)Indirect17.8K shares at avg. $0.61$11K - Apr 7, 2025ACUT
Accustem Sciences Inc.
Purchase(P)Indirect35K shares at avg. $0.65$23K - Mar 18, 2025ACUT
Accustem Sciences Inc.
Purchase(P)Indirect100K shares at avg. $0.45$45K - Dec 31, 2024ACUT
Accustem Sciences Inc.
Purchase(P)Indirect100K shares at avg. $0.38$38K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 21, 2026 |  TLSA Tiziana Life Sciences Ltd | Purchase(P) | 42,357 | $0.99 | $41,933 | Indirect |
| Jul 21, 2026 |  OKYO OKYO Pharma Ltd | Purchase(P) | 22,500 | $1.45 | $32,625 | Indirect |
| Jul 21, 2026 | TLSA Tiziana Life Sciences Ltd | Award(A) | 42,357 | $0.99 | $41,933 | Indirect |
| Jul 21, 2026 | OKYO OKYO Pharma Ltd | Award(A) | 22,500 | $1.45 | $32,625 | Indirect |
| Jul 20, 2026 | OKYO OKYO Pharma Ltd | Purchase(P) | 25,000 | $1.40 | $35,000 | Indirect |
| Jul 20, 2026 | OKYO OKYO Pharma Ltd | Award(A) | 25,000 | $1.40 | $35,000 | Indirect |
| Jun 12, 2026 | TLSA Tiziana Life Sciences Ltd | Purchase(P) | 15,000 | $1.11 | $16,650 | Indirect |
| Jun 12, 2026 | TLSA Tiziana Life Sciences Ltd | Award(A) | 15,000 | $1.11 | $16,650 | Indirect |
| Jun 8, 2026 | OKYO OKYO Pharma Ltd | Award(A) | 300,000 | $1.72 | $516,000 | Indirect |
| Jun 13, 2025 |  ACUT Accustem Sciences Inc. | Purchase(P) | 2,000 | $1.00 | $2,000 | Indirect |
| Jun 13, 2025 | ACUT Accustem Sciences Inc. | Purchase(P) | 400 | $1.10 | $440 | Indirect |
| Jun 12, 2025 | ACUT Accustem Sciences Inc. | Purchase(P) | 8,991 | $0.83 | $7,463 | Indirect |
| Jun 11, 2025 | ACUT Accustem Sciences Inc. | Purchase(P) | 28,205 | $0.39 | $11,000 | Indirect |
| Apr 9, 2025 | ACUT Accustem Sciences Inc. | Purchase(P) | 3,000 | $0.67 | $2,010 | Indirect |
| Apr 8, 2025 | ACUT Accustem Sciences Inc. | Purchase(P) | 35,000 | $0.67 | $23,275 | Indirect |
| Apr 7, 2025 | ACUT Accustem Sciences Inc. | Purchase(P) | 17,802 | $0.61 | $10,841 | Indirect |
| Apr 7, 2025 | ACUT Accustem Sciences Inc. | Purchase(P) | 35,000 | $0.65 | $22,750 | Indirect |
| Mar 18, 2025 | ACUT Accustem Sciences Inc. | Purchase(P) | 100,000 | $0.45 | $44,700 | Indirect |
| Dec 31, 2024 | ACUT Accustem Sciences Inc. | Purchase(P) | 100,000 | $0.38 | $38,100 | Indirect |
1-19 of 19 transactions
About CERRONE GABRIELE M
CERRONE GABRIELE M (SEC CIK 0001139306) files insider reports with the SEC as Director of OKYO Pharma Ltd (OKYO), Director of Tiziana Life Sciences Ltd (TLSA) and Director of Accustem Sciences Inc. (ACUT).
Signal8 holds 16 ownership filings by CERRONE GABRIELE M (2 Form 3, 14 Form 4), filed between Jan 3, 2025 and Aug 7, 2026. Those filings report 19 transactions, from Dec 31, 2024 to Jul 21, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on CERRONE GABRIELE M's filings is in LONDON.
Recent filings by CERRONE GABRIELE M
- Jul 21, 2026: Open-market purchase of TLSA shares (Form 4, code P).
- Jul 21, 2026: Open-market purchase of OKYO shares (Form 4, code P).
- Jul 21, 2026: Grant or award of TLSA shares (Form 4, code A).
- Jul 21, 2026: Grant or award of OKYO shares (Form 4, code A).
- Jul 20, 2026: Open-market purchase of OKYO shares (Form 4, code P).
Other insiders filing for OKYO Pharma Ltd (OKYO)
- BRANCACCIO JOHN P, Director
- Dempsey Robert John, CHIEF EXECUTIVE OFFICER
- JACOB GARY S, CHIEF DEVELOPMENT OFFICER
- Mantelli Flavio, CHIEF MEDICAL OFFICER
- Patil Rajkumar V., Chief Scientific Officer
- Denoyer Bernard, Director